New bacteria slurry takes on poop transplants for stubborn gut infection
NCT ID NCT05911997
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests two treatments for people with repeat C. diff infections: a lab-made bacteria mix called MTC01 and a fecal transplant (FMT) from a healthy donor. Both are given during a colonoscopy. The goal is to see which is safer and better at stopping the infection from coming back. About 60 adults with at least two recent C. diff episodes will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIODIES DIFFICILE INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MTC01 (a slurry of bacteria) and fecal microbiota transplantation (FMT) from a healthy donor
What this could lead to
If successful, this could point toward a safer, more effective treatment for recurrent C. difficile infections, reducing the need for repeated antibiotics.
What could go wrong
This is an early Phase 1 trial with only 60 participants, so results may not apply broadly. There are risks of serious side effects, including infection or allergic reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.